This Educational Series provides an overview of cardiovascular considerations in the long-term management of chronic myeloid leukaemia (CML). In particular, it highlights that the baseline stratification of patients based on comorbidities (especially cardiovascular) should be considered in the selection of initial tyrosine kinase inhibitor (TKI) treatment in CML.
Guiding commentary is provided by Dr. Cecily Forsyth, a clinical haematologist for over 20 years at Central Coast of NSW.
Please login below to download this issue (PDF)